Table 4.

Overall survival and breast cancer-specific survival for breast cancer cases by tumor HER2 receptor status^a

	Inflammatory breast cancer		Locally advanced breast cancer		Metastatic breast cancer		Non-T4 breast cancer
	Positiveb	Not positiveb	Positive	Not positive	Positive	Not positive	Positive	Not positive
Overall mortality
Number of events	400	280	239	131	648	347	4,128	1,397
Number at risk	703	477	484	255	942	506	34,754	9,575
Unadjusted HR (95% CI)	1 (ref)	0.99 (0.85 to 1.15)	1 (ref)	1.01 (0.82 to 1.26)	1 (ref)	0.99 (0.87 to 1.12)	1 (ref)	1.19 (1.12 to 1.27)
Adjusted HR (95% CI)c	1 (ref)	0.87 (0.75 to 1.02)	1 (ref)	1.00 (0.81 to 1.24)	1 (ref)	0.88 (0.77 to 1.01)	1 (ref)	1.05 (0.99 to 1.12)
Breast cancer-specific mortality
Number of events	282	193	132	78	450	266	1,185	556
Number at risk	703	477	484	255	942	506	34,754	9,575
Unadjusted HR (95% CI)	1 (ref)	0.98 (0.81 to 1.17)	1 (ref)	1.11 (0.84 to 1.47)	1 (ref)	1.09 (0.94 to 1.27)	1 (ref)	1.68 (1.52 to 1.86)
Adjusted HR (95% CI)c	1 (ref)	0.82 (0.68 to 0.99)	1 (ref)	0.96 (0.72 to 1.28)	1 (ref)	0.95 (0.82 to 1.11)	1 (ref)	1.16 (1.05 to 1.28)

^aUnivariate and multivariate adjusted analysis of overall survival and breast cancer-specific survival. Data for cases with missing hormone receptor status suppressed from table. ^bData presented as number of cases: not positive, not human epidermal growth factor-like receptor 2 (HER2)-positive; positive, HER2-positive; ref, reference. ^cIncludes adjustment for age (years), ethnicity, grade, socioeconomic status quintile, treatment with surgery, radiation therapy, and chemotherapy. HR, hazards ratio; CI, confidence interval.